COMPUGROUP MEDICAL SE & CO K (COP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:COP - DE000A288904 - Common Stock
22.66 EUR
+0.24 (+1.07%)
COP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 11 industry peers in the Health Care Technology industry. There are concerns on the financial health of COP while its profitability can be described as average. COP is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
COP had positive earnings in the past year.
COP had a positive operating cash flow in the past year.
Each year in the past 5 years COP has been profitable.
In the past 5 years COP always reported a positive cash flow from operatings.
1.2 Ratios
COP has a Return On Assets of 1.34%. This is comparable to the rest of the industry: COP outperforms 50.00% of its industry peers.
COP has a Return On Equity (4.15%) which is comparable to the rest of the industry.
Looking at the Return On Invested Capital, with a value of 3.53%, COP is doing worse than 60.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for COP is significantly below the industry average of 9.09%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 4.15% | ||
| ROIC | 3.53% |
ROA(3y)2.65%
ROA(5y)3.3%
ROE(3y)7.71%
ROE(5y)9.17%
ROIC(3y)4.07%
ROIC(5y)4.45%
1.3 Margins
COP has a Profit Margin (2.34%) which is comparable to the rest of the industry.
COP's Profit Margin has declined in the last couple of years.
With a Operating Margin value of 8.13%, COP perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
In the last couple of years the Operating Margin of COP has declined.
Looking at the Gross Margin, with a value of 83.85%, COP is in the better half of the industry, outperforming 70.00% of the companies in the same industry.
COP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.13% | ||
| PM (TTM) | 2.34% | ||
| GM | 83.85% |
OM growth 3Y-2.61%
OM growth 5Y-10.29%
PM growth 3Y-23.61%
PM growth 5Y-19.42%
GM growth 3Y32.01%
GM growth 5Y16.44%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so COP is destroying value.
Compared to 1 year ago, COP has less shares outstanding
COP has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, COP has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.79, we must say that COP is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.79, COP perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
COP has a debt to FCF ratio of 9.74. This is a negative value and a sign of low solvency as COP would need 9.74 years to pay back of all of its debts.
COP has a Debt to FCF ratio (9.74) which is comparable to the rest of the industry.
COP has a Debt/Equity ratio of 1.22. This is a high value indicating a heavy dependency on external financing.
COP has a Debt to Equity ratio of 1.22. This is amonst the worse of the industry: COP underperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.22 | ||
| Debt/FCF | 9.74 | ||
| Altman-Z | 1.79 |
ROIC/WACC0.67
WACC5.27%
2.3 Liquidity
COP has a Current Ratio of 1.12. This is a normal value and indicates that COP is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of COP (1.12) is worse than 60.00% of its industry peers.
COP has a Quick Ratio of 1.09. This is a normal value and indicates that COP is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of COP (1.09) is worse than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.09 |
3. Growth
3.1 Past
COP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.71%.
COP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.58% yearly.
Looking at the last year, COP shows a decrease in Revenue. The Revenue has decreased by -2.19% in the last year.
The Revenue has been growing by 9.12% on average over the past years. This is quite good.
EPS 1Y (TTM)-45.71%
EPS 3Y-20.77%
EPS 5Y-13.58%
EPS Q2Q%-40%
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y4.02%
Revenue growth 5Y9.12%
Sales Q2Q%0.54%
3.2 Future
The Earnings Per Share is expected to grow by 9.19% on average over the next years. This is quite good.
COP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.36% yearly.
EPS Next Y1.4%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
EPS Next 5YN/A
Revenue Next Year2.47%
Revenue Next 2Y2.65%
Revenue Next 3Y2.49%
Revenue Next 5Y0.36%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 43.58, which means the current valuation is very expensive for COP.
COP's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of COP to the average of the S&P500 Index (26.31), we can say COP is valued expensively.
With a Price/Forward Earnings ratio of 12.88, COP is valued correctly.
COP's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. COP is cheaper than 70.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.59, COP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.58 | ||
| Fwd PE | 12.88 |
4.2 Price Multiples
COP's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. COP is cheaper than 70.00% of the companies in the same industry.
80.00% of the companies in the same industry are more expensive than COP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.34 | ||
| EV/EBITDA | 9.24 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)31.03
PEG (5Y)N/A
EPS Next 2Y4.91%
EPS Next 3Y9.19%
5. Dividend
5.1 Amount
COP has a yearly dividend return of 0.22%, which is pretty low.
COP's Dividend Yield is comparable with the industry average which is at 3.56.
Compared to an average S&P500 Dividend Yield of 2.40, COP's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.22% |
5.2 History
The dividend of COP is nicely growing with an annual growth rate of 14.75%!
Dividend Growth(5Y)14.75%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
191.63% of the earnings are spent on dividend by COP. This is not a sustainable payout ratio.
COP's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP191.63%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
FRA:COP (6/24/2025, 7:00:00 PM)
22.66
+0.24 (+1.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners13.38%
Inst Owner ChangeN/A
Ins Owners53.51%
Ins Owner ChangeN/A
Market Cap1.22B
Revenue(TTM)1.16B
Net Income(TTM)27.00M
Analysts56.67
Price Target21.32 (-5.91%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.22% |
Yearly Dividend1
Dividend Growth(5Y)14.75%
DP191.63%
Div Incr Years2
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.58 | ||
| Fwd PE | 12.88 | ||
| P/S | 1.05 | ||
| P/FCF | 14.34 | ||
| P/OCF | 8.46 | ||
| P/B | 1.87 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.24 |
EPS(TTM)0.52
EY2.29%
EPS(NY)1.76
Fwd EY7.76%
FCF(TTM)1.58
FCFY6.97%
OCF(TTM)2.68
OCFY11.82%
SpS21.51
BVpS12.12
TBVpS-12.86
PEG (NY)31.03
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 4.15% | ||
| ROCE | 5.85% | ||
| ROIC | 3.53% | ||
| ROICexc | 3.83% | ||
| ROICexgc | 41.76% | ||
| OM | 8.13% | ||
| PM (TTM) | 2.34% | ||
| GM | 83.85% | ||
| FCFM | 7.35% |
ROA(3y)2.65%
ROA(5y)3.3%
ROE(3y)7.71%
ROE(5y)9.17%
ROIC(3y)4.07%
ROIC(5y)4.45%
ROICexc(3y)4.31%
ROICexc(5y)4.74%
ROICexgc(3y)36.56%
ROICexgc(5y)51.39%
ROCE(3y)6.74%
ROCE(5y)7.38%
ROICexgc growth 3Y-23.91%
ROICexgc growth 5Y-9.04%
ROICexc growth 3Y-4.3%
ROICexc growth 5Y-14.26%
OM growth 3Y-2.61%
OM growth 5Y-10.29%
PM growth 3Y-23.61%
PM growth 5Y-19.42%
GM growth 3Y32.01%
GM growth 5Y16.44%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.22 | ||
| Debt/FCF | 9.74 | ||
| Debt/EBITDA | 3.86 | ||
| Cap/Depr | 52.61% | ||
| Cap/Sales | 5.11% | ||
| Interest Coverage | 2.54 | ||
| Cash Conversion | 69.81% | ||
| Profit Quality | 314.42% | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z | 1.79 |
F-Score6
WACC5.27%
ROIC/WACC0.67
Cap/Depr(3y)60.99%
Cap/Depr(5y)64.22%
Cap/Sales(3y)5.98%
Cap/Sales(5y)6.31%
Profit Quality(3y)175.79%
Profit Quality(5y)158.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.71%
EPS 3Y-20.77%
EPS 5Y-13.58%
EPS Q2Q%-40%
EPS Next Y1.4%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y4.02%
Revenue growth 5Y9.12%
Sales Q2Q%0.54%
Revenue Next Year2.47%
Revenue Next 2Y2.65%
Revenue Next 3Y2.49%
Revenue Next 5Y0.36%
EBIT growth 1Y-18.88%
EBIT growth 3Y1.31%
EBIT growth 5Y-2.11%
EBIT Next Year77.58%
EBIT Next 3Y24.98%
EBIT Next 5Y17.79%
FCF growth 1Y3.01%
FCF growth 3Y-11.08%
FCF growth 5Y-0.24%
OCF growth 1Y-8.49%
OCF growth 3Y-7.96%
OCF growth 5Y3.13%
COMPUGROUP MEDICAL SE & CO K / COP.DE FAQ
What is the ChartMill fundamental rating of COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to COP.DE.
What is the valuation status of COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to COMPUGROUP MEDICAL SE & CO K (COP.DE). This can be considered as Overvalued.
How profitable is COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?
COMPUGROUP MEDICAL SE & CO K (COP.DE) has a profitability rating of 4 / 10.
What is the valuation of COMPUGROUP MEDICAL SE & CO K based on its PE and PB ratios?
The Price/Earnings (PE) ratio for COMPUGROUP MEDICAL SE & CO K (COP.DE) is 43.58 and the Price/Book (PB) ratio is 1.87.
What is the financial health of COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?
The financial health rating of COMPUGROUP MEDICAL SE & CO K (COP.DE) is 2 / 10.